Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Triple Negative Breast Neoplasms 7Breast Neoplasms 6Carcinoma, Non-Small-Cell Lung 3Uterine Cervical Neoplasms 2Solid Tumor 2Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Nasopharyngeal Carcinoma 2Melanoma 2Gastrointestinal Stromal Tumors 2Colorectal Neoplasms 2Cervical Cancer Metastatic 2Carcinoma, Renal Cell 2Thyroid Neoplasms 1Recurrence 1Non-squamous Non-small-cell Lung Cancer 1Non Squamous Non Small Cell Lung 1Neoplasms 1Neoplasm Metastasis 1Neoadjuvant Therapy 1NSCLC 1Gastro-enteropancreatic neuroendocrine tumor 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Disease Progression 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1BRCA-Mutated Breast Carcinoma 1Advanced Solid Tumor 1Advanced NSCLC 1

Interventions

Lenalidomide 4Gemcitabine 4Dexamethasone 4Cyclophosphamide 4Bortezomib 4Nivolumab 3Cisplatin 3Carboplatin 3vandetanib 2tumor necrosis factor-alpha, CNGRC fusion protein, human 2pomalidomide 2pembrolizumab 2liposomal doxorubicin 2fludarabine 2durvalumab 2capivasertib 2Radiosurgery 2Paclitaxel 2Doxorubicin 2Bevacizumab 2Anthropogenic Effects 2venetoclax 1umbralisib 1ublituximab 1tremelimumab 1tivozanib 1ricolinostat 1regorafenib 1pazopanib 1niraparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Disease Progression × famitinib × Clear all
NCT04044378 2020-05-19

Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma

Peking University People's Hospital

Phase 1/2 Withdrawn

Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡